NO20072878L - Antitrombotiske dobbelt inhibitorer omfattende en biotin-rest - Google Patents
Antitrombotiske dobbelt inhibitorer omfattende en biotin-restInfo
- Publication number
- NO20072878L NO20072878L NO20072878A NO20072878A NO20072878L NO 20072878 L NO20072878 L NO 20072878L NO 20072878 A NO20072878 A NO 20072878A NO 20072878 A NO20072878 A NO 20072878A NO 20072878 L NO20072878 L NO 20072878L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- residue
- oligosaccharide
- quinolinyl
- iso
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 6
- 230000002785 anti-thrombosis Effects 0.000 title abstract 3
- 229960002685 biotin Drugs 0.000 title abstract 3
- 235000020958 biotin Nutrition 0.000 title abstract 3
- 239000011616 biotin Substances 0.000 title abstract 3
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000002482 oligosaccharides Chemical class 0.000 abstract 4
- 229920001542 oligosaccharide Polymers 0.000 abstract 3
- -1 1,2,3,4-tetrahydronaphthyl Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical group C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 abstract 1
- 108090001008 Avidin Proteins 0.000 abstract 1
- 108010090804 Streptavidin Proteins 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001858 anti-Xa Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04106964 | 2004-12-23 | ||
| PCT/EP2005/057011 WO2006067173A2 (en) | 2004-12-23 | 2005-12-21 | Antithrombotic dual inhibitors comprising a biotin residue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072878L true NO20072878L (no) | 2007-09-17 |
Family
ID=35160114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072878A NO20072878L (no) | 2004-12-23 | 2007-06-06 | Antitrombotiske dobbelt inhibitorer omfattende en biotin-rest |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8168595B2 (pt) |
| EP (1) | EP1830887B1 (pt) |
| JP (2) | JP5130051B2 (pt) |
| KR (1) | KR101284922B1 (pt) |
| CN (1) | CN101087622A (pt) |
| AR (1) | AR053657A1 (pt) |
| AT (1) | ATE500846T1 (pt) |
| AU (1) | AU2005318134B2 (pt) |
| BR (1) | BRPI0518560A2 (pt) |
| CA (1) | CA2592436C (pt) |
| DE (1) | DE602005026859D1 (pt) |
| DK (1) | DK1830887T3 (pt) |
| ES (1) | ES2361921T3 (pt) |
| HR (1) | HRP20110330T1 (pt) |
| IL (2) | IL183713A (pt) |
| MX (1) | MX2007007837A (pt) |
| MY (1) | MY146121A (pt) |
| NO (1) | NO20072878L (pt) |
| NZ (1) | NZ555739A (pt) |
| PE (1) | PE20060773A1 (pt) |
| PL (1) | PL1830887T3 (pt) |
| PT (1) | PT1830887E (pt) |
| RU (1) | RU2403259C2 (pt) |
| SI (1) | SI1830887T1 (pt) |
| TW (1) | TWI403334B (pt) |
| UA (1) | UA88793C2 (pt) |
| WO (1) | WO2006067173A2 (pt) |
| ZA (1) | ZA200705088B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI403334B (zh) * | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
| JP6109574B2 (ja) | 2009-12-18 | 2017-04-05 | カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ | 合成オリゴサッカリドを含有する医薬経口剤形 |
| FR2974478A1 (fr) | 2011-04-28 | 2012-11-02 | Endotis Pharma | Conjugues d'oligosaccharides en prevention des lesions d'ischemie-reperfusion |
| EP2721044B1 (en) | 2011-06-17 | 2015-11-18 | Carbomimetics | Synthetic pentasaccharides having short half-life and high activity |
| WO2013007762A1 (en) | 2011-07-11 | 2013-01-17 | Endotis Pharma | Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure |
| WO2016176426A1 (en) | 2015-04-28 | 2016-11-03 | Duke University | Thrombus imaging aptamers and methods of using same |
| EP3512526A4 (en) | 2016-09-16 | 2020-05-27 | Duke University | VON WILLEBRAND FACTOR (VWF) TARGETING AGENTS AND METHODS OF USE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| EP0454220B1 (en) | 1990-04-23 | 1993-08-18 | Akzo Nobel N.V. | Carbohydrate derivatives comprising a trisaccharide unit |
| IL102758A (en) | 1991-08-23 | 1997-03-18 | Akzo Nv | Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them |
| NZ264340A (en) | 1993-09-01 | 1995-04-27 | Akzo Nobel Nv | Bisconjugate comprising two saccharides and a spacer, use in pharmaceutical compositions |
| FR2749849B1 (fr) * | 1996-06-14 | 1998-09-04 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2751334B1 (fr) * | 1996-07-19 | 1998-10-16 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2773801B1 (fr) | 1998-01-19 | 2000-05-12 | Sanofi Sa | Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant |
| FR2773804B1 (fr) | 1998-01-19 | 2000-02-18 | Sanofi Sa | Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant |
| WO1999065934A1 (en) * | 1998-06-17 | 1999-12-23 | Akzo Nobel N.V. | Antithrombotic compounds |
| TWI289566B (en) * | 1999-12-07 | 2007-11-11 | N.V.Organon | Antithrombotic compound |
| FR2814463B1 (fr) * | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
| TWI403334B (zh) * | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
| CN101312747B (zh) * | 2005-10-10 | 2013-03-20 | Msd欧斯股份有限公司 | 包括生物素标记的抗血栓形成双重抑制剂 |
-
2005
- 2005-12-14 TW TW094144361A patent/TWI403334B/zh not_active IP Right Cessation
- 2005-12-16 PE PE2005001503A patent/PE20060773A1/es not_active Application Discontinuation
- 2005-12-20 MY MYPI20056026A patent/MY146121A/en unknown
- 2005-12-21 WO PCT/EP2005/057011 patent/WO2006067173A2/en not_active Ceased
- 2005-12-21 KR KR1020077017005A patent/KR101284922B1/ko not_active Expired - Fee Related
- 2005-12-21 RU RU2007127859/04A patent/RU2403259C2/ru not_active IP Right Cessation
- 2005-12-21 DK DK05821769.6T patent/DK1830887T3/da active
- 2005-12-21 PL PL05821769T patent/PL1830887T3/pl unknown
- 2005-12-21 BR BRPI0518560-2A patent/BRPI0518560A2/pt not_active IP Right Cessation
- 2005-12-21 AU AU2005318134A patent/AU2005318134B2/en not_active Expired
- 2005-12-21 CN CNA2005800444919A patent/CN101087622A/zh active Pending
- 2005-12-21 UA UAA200706654A patent/UA88793C2/ru unknown
- 2005-12-21 HR HR20110330T patent/HRP20110330T1/hr unknown
- 2005-12-21 SI SI200531279T patent/SI1830887T1/sl unknown
- 2005-12-21 AT AT05821769T patent/ATE500846T1/de active
- 2005-12-21 EP EP05821769A patent/EP1830887B1/en not_active Expired - Lifetime
- 2005-12-21 CA CA2592436A patent/CA2592436C/en not_active Expired - Lifetime
- 2005-12-21 JP JP2007547509A patent/JP5130051B2/ja not_active Expired - Lifetime
- 2005-12-21 MX MX2007007837A patent/MX2007007837A/es active IP Right Grant
- 2005-12-21 DE DE602005026859T patent/DE602005026859D1/de not_active Expired - Lifetime
- 2005-12-21 NZ NZ555739A patent/NZ555739A/en not_active IP Right Cessation
- 2005-12-21 PT PT05821769T patent/PT1830887E/pt unknown
- 2005-12-21 US US11/722,444 patent/US8168595B2/en active Active
- 2005-12-21 ES ES05821769T patent/ES2361921T3/es not_active Expired - Lifetime
- 2005-12-22 AR ARP050105472A patent/AR053657A1/es not_active Application Discontinuation
-
2007
- 2007-06-06 IL IL183713A patent/IL183713A/en not_active IP Right Cessation
- 2007-06-06 NO NO20072878A patent/NO20072878L/no not_active Application Discontinuation
- 2007-06-13 ZA ZA200705088A patent/ZA200705088B/xx unknown
-
2011
- 2011-12-18 IL IL217047A patent/IL217047A0/en unknown
-
2012
- 2012-04-04 US US13/439,012 patent/US20120238512A1/en not_active Abandoned
- 2012-04-04 US US13/438,905 patent/US8445450B2/en not_active Expired - Lifetime
- 2012-09-14 JP JP2012202307A patent/JP5632886B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072878L (no) | Antitrombotiske dobbelt inhibitorer omfattende en biotin-rest | |
| KR102090780B1 (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| US6541488B1 (en) | Compositions for treating arterial thrombosis and a factor Xa inhibitor | |
| NO20061251L (no) | Fenyl eller pyridylamidforbindelser som prostaglanding-E2-antagonister | |
| NO20065573L (no) | Orto-substituerte aryl eller heteroarylamidforbindelser | |
| ZA200407295B (en) | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors. | |
| WO2003057225A3 (en) | Phosphate transport inhibitors | |
| UA114856C2 (uk) | Способи лікування із застосуванням похідних арилметоксіізоіндоліну | |
| ATE211147T1 (de) | Tripeptidisches antithrombotisches mittel | |
| ATE164575T1 (de) | Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer | |
| NZ508623A (en) | Antithrombotic peptide compounds with saccharide radicals | |
| UA83648C2 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| EP2352501B1 (en) | Compounds for use in the treatment of osteoporosis | |
| SK132193A3 (en) | Antibiotic compounds | |
| NO20043951L (no) | 3-cyklyl-5-(nitrogenholdig 5-leddet ring) metyl-oksazolidinon-derivater og deres anvendelse som antibakterielle midler | |
| NO20054778L (no) | Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer | |
| WO2007042470A3 (en) | Antithrombotic compound | |
| EA200000389A2 (ru) | Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции | |
| NO922358L (no) | Tert.-butylfenyl-1-amino-4-hydroksybutanderivater, fremgangsmaate ved deres fremstilling og farmasoeytiske preparaterinneholdende forbindelsene | |
| NO20083857L (no) | Piperidinderivater som CXCR3-reseptorantagonister | |
| EA012587B1 (ru) | Биотинилированные гексадекасахариды, их получение и применение | |
| MY145269A (en) | Antithrombotic dual inhibitors comprising a biotin label | |
| MXPA05008190A (es) | Derivado de oligosacarido. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |